Welcome to the e-CCO Library!

P666: Long-term effectiveness and safety of vedolizumab (VDZ) in inflammatory bowel disease (IBD): Results from the Spanish ENEIDA Registry
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Chaparro1,2,3,4*, A. Garre1,2,3,4, I. Alfaro4,5, M. Iborra4,6, P. Mesonero7, I. Vera Mendoza8, A. Rodríguez9, J. Miquel-Cusachs10, S. Riestra11, P. Navarro12, L. De Castro Parga13, C. González-Muñoza14, M. Rivero Tirado15, M. Mañosa4,16, L. Fernández Salazar17, M. García-Sepulcre18, J. Guardiola19, J. Cabriada20, A. Gutiérrez Casbas4,21, B. Sicilia22, J.L. Pérez Calle23, M. Piqueras24, I. Guerra25, O. Roncero26, M. Navarro-Llavat27, E. Sainz28, J. Barrio29, X. Calvet4,30, A. García31, M. Llorente Barrio32, R. Lorente33, P. Almela34, R. Madrigal35, A.J. Lucendo Villarín36, R. Pajares37, M. Van Domselaar38, J. Legido Gil39, J.P. Gisbert1,2,3,4

Created: Thursday, 21 February 2019, 9:14 AM
P666: Safety of combination biologic and immunosuppressive therapy post-orthotopic liver transplantation in patients with inflammatory bowel disease: a systematic review
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Al Draiweesh*1,2, C. Ma1,3, M. Alkhattabi1,4, T. Nguyen5, M. Brahmania1, V. Jairath1,6

Created: Friday, 22 February 2019, 9:41 AM
P666: Short-term outcomes of adalimumab for patients with Crohn's disease and associated prognostic factors: a multicentre retrospective cohort study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Nasuno M.*1, Tanaka H.1, Miyakawa M.1, Motoya S.1, Ishii M.2, Shiotani A.2, Yamashita M.3, Itoh F.3, Tanuma T.4, Sakemi R.5, So S.5, Suzuki R.6, Yanagisawa H.7, Onodera K.8, Kaneto H.9, Nojima M.10, Nakase H.8

Created: Wednesday, 20 February 2019, 10:36 AM
P666: Trend of Lower gastrointestinal Endoscopy in Patients with Inflammatory Bowel Diseases : A Nationwide Population-Based Study in South Korea
Year: 2022
Source: ECCO'22
Authors: Kim, S.(1);Lee, S.(2);Han, K.(2);Soh, H.(1);Koh, S.J.(3);Lee, H.J.(1);Im, J.P.(1);Kim, J.S.(1);
Created: Friday, 11 February 2022, 3:56 PM
P667 Combined therapy of perianal fistulas with autologous adipose-derived stem cells
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Surowiecka, M. Łodyga, M. Durlik, R. Grażyna

Created: Thursday, 30 January 2020, 10:12 AM
P667: Characterization of a large Hispanic cohort with Inflammatory Bowel Disease across a 25-year span
Year: 2021
Source: ECCO'21 Virtual
Authors: Torres, E.A.(1);Ramos, L.(1);Sanchez, A.(1);Amaya, C.(2);Perez-Gilbe, A.(3);
Created: Wednesday, 2 June 2021, 4:12 PM
P667: Safety of anti-TNF treatment in liver transplant recipients – a meta-analysis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Westerouen van Meeteren M.1, Inderson A.1, Hayee B.2, van der Meulen A.1, Altwegg R.3, van Hoek B.1, Pageaux G.-P.3, Stijnen T.4, Stein D.5, Maljaars J.*1

Created: Wednesday, 20 February 2019, 10:36 AM
P667: Standard vs. intensified infliximab rescue therapy for hospitalised paediatric patients with acute severe exacerbations of colitis-predominant inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

K.S. Singh1*, L. Hart2, A. Al Khoury1, C.-Y. Chao2,3, W. Afif2, P.L. Lakatos2, N. Ahmed4, T. Bessissow2

Created: Thursday, 21 February 2019, 9:14 AM
P667: Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates in 72 patients, a report from a district general hospital
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

P. Radhakrishnan*1, H. Johnson1, K. Wade1, S. McLaughlin1

Created: Friday, 22 February 2019, 9:41 AM
P667: Unmet needs in the management of Inflammatory Bowel Diseases in Egypt
Year: 2022
Source: ECCO'22
Authors: KhorshidFASGE, M.(1);Abdel-Gawad, M.(2);AbdAllah, M.(3);Tag-Adeen, M.(4);Afify, S.(5);El Deeb, R.(6);Elshaarawy, O.(7);Elbasiony, M.(8);Bassuny, A.N.(9);El-Raey, F.(10);Fathy, H.(11);ElShabacy, O.(12);Cordie, A.(13);Abdelmoaty, A.(14);Elbahr, O.(7);Ali-Eldin, Z.(15);Alboraie, M.(16);
Created: Friday, 11 February 2022, 3:56 PM
P667: USTEkinumAb Double intravenous loading induction therapY at week 0,4 in patients with Crohn's Disease– results from STEADY study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Chin, A.(1)*;Jeffrey, A.(1);Teh, W.L.(1);Menon, S.(1);So, K.(1);Venugopal, K.(1);Picardo, S.(1);
Created: Friday, 14 July 2023, 11:12 AM
P668 Real-life comparison of different anti-TNF biologic therapies for ulcerative colitis treatment: A retrospective cohort study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B. Barberio, F. Zingone, R. D’Incà, C. Marinelli, M.C. Maccarone, A. Gubbiotti, L. Cingolani, G. Lorenzon, M. Ghisa, E.V. Savarino

Created: Thursday, 30 January 2020, 10:12 AM
P668: Differential efficacy of biologic agents for Inflammatory Bowel Disease Unclassified and comparison with Ulcerative Colitis: a propensity score analysis of 4054 patients from the UK IBD BioResource
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Kapizioni, C.(1)*;Desoki, R.(1,2);Balendran, K.(1);Lam, D.(1);Shawky, R.(3);Pele, L.(3);Parkes, M.(1);Raine, T.(1);
Created: Friday, 14 July 2023, 11:12 AM
P668: Does biotin deficiency play a role in the pathogenesis of Inflammatory Bowel Disease? Preliminary results of a cross-sectional study
Year: 2021
Source: ECCO'21 Virtual
Authors: Erbach, J.(1);Arnold, A.(2);Bonn, F.(2);Stein, J.M.(1,3,4);Schröder, O.(1,3);Aksan, A.(1,5);
Created: Wednesday, 2 June 2021, 4:12 PM
P668: Measured and modelled data suggest that oral administration of V565, a novel domain antibody to TNF-alpha, could be beneficial in the treatment of IBD
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Nurbhai1*, M. West1, T. MacDonald2, G. Parkes3, P. Irving4, A. Vossenkaemper2, S. Crowe1

Created: Thursday, 21 February 2019, 9:14 AM
P668: Post-marketing experience of vedolizumab in inflammatory bowel disease: analysis of pneumonia and other respiratory tract infections
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Bhayat F.1, Blake A.*2, Travis S.3

Created: Wednesday, 20 February 2019, 10:36 AM
P668: Real world use and adverse events of SARs-CoV-2 vaccination in Greek patients with Inflammatory Bowel Disease
Year: 2022
Source: ECCO'22
Authors: Orfanoudaki, E.(1);Zacharopoulou, E.(2);Kitsou, V.(3);Karmiris, K.(4);Theodoropoulou, A.(4);Mantzaris , G.J.(5);Tzouvala, M.(2);Michopoulos , S.(6);Zampeli, E.(6);Michalopoulos, G.(7);Karatzas, P.(8);Viazis, N.(5);Liatsos, C.(9);Bamias, G.(10);Koutroubakis, I.E.(1);
Created: Friday, 11 February 2022, 3:56 PM
P668: Ustekinumab induction effectiveness in Crohn’s disease in a real-life cohort
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Rullan1, A. Elosua*1, C. Saldaña1, E. Amorena1, M. Vicuña1, S. Rubio1, Ó. Nantes1, C. Rodríguez1

Created: Friday, 22 February 2019, 9:41 AM
P669 Adherence to self-administered biologic therapies in inflammatory bowel disease: Experience in a tertiary hospital
Year: 2020
Source:

ECCO'20 Vienna

Authors:

L. Ramos Lopez1, J. Ramos Rodríguez2, R. De La Barreda1, F. Guitierrez2, G.J. Nazco Casariego2, I. Alonso Abreu1, M. Carrillo Palau1, E. Quintero1

Created: Thursday, 30 January 2020, 10:12 AM
P669: Adalimumab long-term effectiveness in adalimumab-naïve patients with Crohn's disease: final data from PYRAMID registry
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Loftus Jr. E.*1, D'Haens G.2, Reinisch W.3, Satsangi J.4, Panaccione R.5, Berg S.6, Alperovich G.7, Bereswill M.8, Kalabic J.8, Skup M.9, Petersson J.9, Robinson A.M.9

Created: Wednesday, 20 February 2019, 10:36 AM